Quoin Pharmaceuticals Provides Clinical Update on QRX003
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy QNRX?
Source: NASDAQ.COM
- FDA Meeting Outcome: Quoin Pharmaceuticals learned during its Type C meeting with the FDA that a single Phase 3 study may suffice for U.S. marketing approval of QRX003 for Netherton Syndrome, significantly reducing the clinical burden compared to the initially contemplated two studies, potentially accelerating the product's market entry.
- Flexibility in Trial Design: The FDA expressed openness to alternative clinical trial designs, such as randomized withdrawal or randomized delayed start, which provides Quoin with greater flexibility in designing the pivotal Phase 3 study, aiding in optimizing the study protocol to meet regulatory requirements.
- Stock Price Volatility Ahead of Earnings: Quoin's stock price fell 6.36% to $8.68 in pre-market trading, reflecting market caution ahead of its upcoming fourth-quarter and full-year 2025 financial results, which may impact investor sentiment and future stock performance.
- Diverse Product Pipeline: Quoin's pipeline includes candidates targeting various rare diseases, with QRX003 also being explored for Peeling Skin Syndrome and other conditions, showcasing the company's broad positioning in the rare disease sector and potential market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNRX
Wall Street analysts forecast QNRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.410
Low
70.00
Averages
70.00
High
70.00
Current: 6.410
Low
70.00
Averages
70.00
High
70.00
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quoin Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Surprise: Quoin Pharmaceuticals reported a Q4 GAAP EPS of -$1.74, beating expectations by $2.28, indicating an improvement in financial performance despite still being in a loss position.
- Strong Cash Reserves: As of December 31, 2025, Quoin had approximately $18.7 million in cash, cash equivalents, and marketable securities, providing a solid financial cushion for future operations.
- Operational Funding Outlook: The company believes its year-end cash position will sustain operations into 2027, reflecting a prudent approach to cash management that supports long-term growth.
- Increased Market Attention: Following the earnings release, Quoin Pharmaceuticals has garnered heightened market interest, with investors showing greater curiosity about its future profitability and cash flow management.
See More
Quoin Pharmaceuticals Shares Surge 20% on FDA Feedback for QRX003
- Positive FDA Feedback: Quoin Pharmaceuticals received encouraging news from the FDA regarding its lead drug QRX003 for treating Netherton Syndrome, indicating that a single Phase 3 trial may suffice for U.S. approval, leading to a more than 20% surge in pre-market trading.
- Trial Design Flexibility: The FDA also expressed openness to alternative trial designs that may not require a traditional placebo group, providing Quoin with greater flexibility in its clinical trials and potentially reducing development risks.
- Advancing Phase 3 Plans: Following the positive feedback from the FDA, Quoin plans to advance its Phase 3 clinical trial program and aims to file for approval as early as 2027, demonstrating the company's confidence and commitment to addressing Netherton Syndrome.
- Clinical Network Advantage: CEO Michael Myers stated that with their established network of U.S. and EU clinical trial sites, Quoin is confident in initiating its pivotal Phase 3 program and completing patient enrollment this year, further solidifying its market position.
See More
QNRX Shares Jump 20% in Pre-Market Trading – FDA's Comments on Netherton Syndrome Treatment?
Stock Surge: Shares of Quoin Pharmaceuticals (QNRX) increased by over 20% in pre-market trading following positive feedback from the FDA regarding its lead drug QRX003 for treating Netherton syndrome.
FDA Trial Insights: The FDA indicated that a single Phase 3 trial may suffice for U.S. approval, which is a departure from the usual requirement of two studies, and showed openness to alternative trial designs.
Future Plans: Quoin Pharmaceuticals plans to advance its Phase 3 program and is on track to complete patient enrollment this year, with potential for filing for approval as early as 2027.
CEO's Confidence: CEO Michael Myers expressed confidence in the company's established network of clinical trial sites in the U.S. and EU, indicating readiness to initiate the pivotal Phase 3 program.
See More
Quoin Pharmaceuticals Advances NETHERTON NOW Awareness Campaign
- Campaign Effectiveness: Quoin Pharmaceuticals' NETHERTON NOW awareness campaign, launched in 2025, has achieved nearly 2 million video views and over 24 million global impressions, significantly raising awareness of Netherton Syndrome and enabling patients and families to share their experiences, thereby enhancing societal understanding of this rare disease.
- Power of Patient Stories: By sharing patient and caregiver narratives, NETHERTON NOW has not only given a voice to previously silent sufferers but also fostered greater recognition of Netherton Syndrome within the medical and advocacy communities, driving attention to this long-neglected condition.
- New Video Release: Coinciding with Rare Disease Day, Quoin released its latest video,
See More
Quoin Pharmaceuticals Files for Breakthrough Designation for QRX003, Potential First Treatment for Netherton Syndrome
- Breakthrough Application: Quoin Pharmaceuticals has filed for Breakthrough Medicine Designation for QRX003 with the Saudi Food and Drug Authority, which, if granted, will expedite the review process and potentially allow early patient access by the second half of 2026, marking a historic milestone in the treatment of Netherton Syndrome.
- Clinical Trial Progress: QRX003 is currently undergoing two pivotal whole-body clinical trials, with enrollment expected to complete in the first half of 2026 and top-line data anticipated in the second half, providing critical evidence for subsequent drug applications and facilitating market entry.
- Significant Market Potential: If approved, QRX003 will be the first-ever treatment for Netherton Syndrome globally, and Quoin's distribution partnership with Genpharm will ensure its promotion in Saudi Arabia and other MENA countries, addressing the urgent need for rare disease therapies in the region.
- Regulatory Support Strengthened: QRX003 has received Orphan Drug and Pediatric Rare Disease Designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency, indicating strong regulatory recognition worldwide and enhancing Quoin's competitive position in the rare disease market.
See More
Quoin Pharmaceuticals Stock Rises 21% Following Topical Rapamycin Achievement
Stock Performance: Quoin Pharmaceuticals Ltd. (QNRX) saw a 21.15% increase in stock price, reaching $9.99, following the announcement of successful rapamycin loadings in their topical delivery platforms.
Clinical Development Plans: The company intends to manufacture clinical trial and stability batches in Q4 2025 and start clinical testing in the first half of 2026 for conditions like microcystic lymphatic malformations and venous malformations, which currently have no FDA-approved treatments.
Trading Activity: The announcement led to unusually high trading volume for QNRX, indicating strong investor interest in the company's developments.
Stock Range: The stock's 52-week price range is noted to be between $2.65 and $9.99.
See More
Quoin Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Surprise: Quoin Pharmaceuticals reported a Q4 GAAP EPS of -$1.74, beating expectations by $2.28, indicating an improvement in financial performance despite still being in a loss position.
- Strong Cash Reserves: As of December 31, 2025, Quoin had approximately $18.7 million in cash, cash equivalents, and marketable securities, providing a solid financial cushion for future operations.
- Operational Funding Outlook: The company believes its year-end cash position will sustain operations into 2027, reflecting a prudent approach to cash management that supports long-term growth.
- Increased Market Attention: Following the earnings release, Quoin Pharmaceuticals has garnered heightened market interest, with investors showing greater curiosity about its future profitability and cash flow management.
See More
Quoin Pharmaceuticals Shares Surge 20% on FDA Feedback for QRX003
- Positive FDA Feedback: Quoin Pharmaceuticals received encouraging news from the FDA regarding its lead drug QRX003 for treating Netherton Syndrome, indicating that a single Phase 3 trial may suffice for U.S. approval, leading to a more than 20% surge in pre-market trading.
- Trial Design Flexibility: The FDA also expressed openness to alternative trial designs that may not require a traditional placebo group, providing Quoin with greater flexibility in its clinical trials and potentially reducing development risks.
- Advancing Phase 3 Plans: Following the positive feedback from the FDA, Quoin plans to advance its Phase 3 clinical trial program and aims to file for approval as early as 2027, demonstrating the company's confidence and commitment to addressing Netherton Syndrome.
- Clinical Network Advantage: CEO Michael Myers stated that with their established network of U.S. and EU clinical trial sites, Quoin is confident in initiating its pivotal Phase 3 program and completing patient enrollment this year, further solidifying its market position.
See More
QNRX Shares Jump 20% in Pre-Market Trading – FDA's Comments on Netherton Syndrome Treatment?
Stock Surge: Shares of Quoin Pharmaceuticals (QNRX) increased by over 20% in pre-market trading following positive feedback from the FDA regarding its lead drug QRX003 for treating Netherton syndrome.
FDA Trial Insights: The FDA indicated that a single Phase 3 trial may suffice for U.S. approval, which is a departure from the usual requirement of two studies, and showed openness to alternative trial designs.
Future Plans: Quoin Pharmaceuticals plans to advance its Phase 3 program and is on track to complete patient enrollment this year, with potential for filing for approval as early as 2027.
CEO's Confidence: CEO Michael Myers expressed confidence in the company's established network of clinical trial sites in the U.S. and EU, indicating readiness to initiate the pivotal Phase 3 program.
See More
Quoin Pharmaceuticals Advances NETHERTON NOW Awareness Campaign
- Campaign Effectiveness: Quoin Pharmaceuticals' NETHERTON NOW awareness campaign, launched in 2025, has achieved nearly 2 million video views and over 24 million global impressions, significantly raising awareness of Netherton Syndrome and enabling patients and families to share their experiences, thereby enhancing societal understanding of this rare disease.
- Power of Patient Stories: By sharing patient and caregiver narratives, NETHERTON NOW has not only given a voice to previously silent sufferers but also fostered greater recognition of Netherton Syndrome within the medical and advocacy communities, driving attention to this long-neglected condition.
- New Video Release: Coinciding with Rare Disease Day, Quoin released its latest video,
See More
Quoin Pharmaceuticals Files for Breakthrough Designation for QRX003, Potential First Treatment for Netherton Syndrome
- Breakthrough Application: Quoin Pharmaceuticals has filed for Breakthrough Medicine Designation for QRX003 with the Saudi Food and Drug Authority, which, if granted, will expedite the review process and potentially allow early patient access by the second half of 2026, marking a historic milestone in the treatment of Netherton Syndrome.
- Clinical Trial Progress: QRX003 is currently undergoing two pivotal whole-body clinical trials, with enrollment expected to complete in the first half of 2026 and top-line data anticipated in the second half, providing critical evidence for subsequent drug applications and facilitating market entry.
- Significant Market Potential: If approved, QRX003 will be the first-ever treatment for Netherton Syndrome globally, and Quoin's distribution partnership with Genpharm will ensure its promotion in Saudi Arabia and other MENA countries, addressing the urgent need for rare disease therapies in the region.
- Regulatory Support Strengthened: QRX003 has received Orphan Drug and Pediatric Rare Disease Designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency, indicating strong regulatory recognition worldwide and enhancing Quoin's competitive position in the rare disease market.
See More
Quoin Pharmaceuticals Stock Rises 21% Following Topical Rapamycin Achievement
Stock Performance: Quoin Pharmaceuticals Ltd. (QNRX) saw a 21.15% increase in stock price, reaching $9.99, following the announcement of successful rapamycin loadings in their topical delivery platforms.
Clinical Development Plans: The company intends to manufacture clinical trial and stability batches in Q4 2025 and start clinical testing in the first half of 2026 for conditions like microcystic lymphatic malformations and venous malformations, which currently have no FDA-approved treatments.
Trading Activity: The announcement led to unusually high trading volume for QNRX, indicating strong investor interest in the company's developments.
Stock Range: The stock's 52-week price range is noted to be between $2.65 and $9.99.
See More
